Blueprint Medicines Corporation Stock News

While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key me

Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.

Blueprint Medicines Corporation (BPMC) Q4 2023 Earnings Call Transcript

Blueprint Medicines (BPMC) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.04. This compares to loss of $2.65 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for Blueprint Medicines (BPMC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared d

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid

Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.

Cogent Biosciences Inc. shares COGT, -1.48% fell more than 30% premarket on Monday after the company over the weekend released clinical trial data on its lead drug candidate that failed to outshine po

Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.

Blueprint Medicines delivered an exceptional quarter with a positive reception for Ayvakit in its first full-quarter post-launch. More than 800 patients were using the ISM treatment at the end of Q3.

Blueprint Medicines (BPMC) came out with a quarterly loss of $2.20 per share versus the Zacks Consensus Estimate of a loss of $2.39. This compares to loss of $2.23 per share a year ago.

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.